Loading clinical trials...

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688•Aerie Pharmaceuticals

View on ClinicalTrials.gov

Summary

To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female subjects (aged 18 or older)
•2. Subjects diagnosed with open-angle glaucoma or ocular hypertension, and determined by the treating physician to require additional intraocular pressure (IOP)-lowering treatment with netarsudil 0.02%.
•3. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing questionnaires and completing laboratory tests

Exclusion Criteria

•1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation
•2. Women of childbearing potential who are pregnant, nursing, or planning a pregnancy and not using a medically acceptable form of birth control. Male subjects with a female partner of childbearing potential must have had a prior vasectomy or agree to use an effective method of birth control during the treatment period and for 3 months after the subject has completed the study.
•3. Known sensitivity or allergy to the study medication or components
•4. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results
•5. Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Baseline Visit

Locations (22)

Atlantis Eyecare

Huntington Beach, California, United States

Harvard Eye Associates

Laguna Hills, California, United States

North Bay Eye Associates, Inc

Petaluma, California, United States

Shettle Eye Research Inc

Largo, Florida, United States

Center For Sight

Sarasota, Florida, United States

Coastal Research Associates, LLC

Roswell, Georgia, United States

Wheaton Eye Clinic, Ltd

Wheaton, Illinois, United States

Stiles Eyecare Excellence and Glaucoma Institute, PA

Overland Park, Kansas, United States

Gaddie Eye Centers, LLC

Louisville, Kentucky, United States

Glaucoma Consultants

Baltimore, Maryland, United States

Key Dates

Start Date

December 27, 2018

Primary Completion Date

July 26, 2019

Completion Date

July 26, 2019

Last Updated

September 29, 2020

Enrollment

261

ACTUAL participants

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

Netarsudil Ophthalmic Solution 0.02%

DRUG

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Feasibility Clinical Evaluation of the Calibreye System

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT